Skip to main content

RDHL

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

RDHL Price
Price Chart

Forward-looking statistics

Beta
1.43
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

redhill biopharma is a biopharmaceutical company focused primarily on development of late clinical-stage new, improved and patented formulations of existing drugs. redhill has an experienced management team, board of directors and advisory board based in israel, the us, canada and europe, with successful track record at big and small pharma of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees101
Market cap$13.8M

Fundamentals

Enterprise value$25.0B
Revenue$8.0M
Revenue per employee
Profit margin-102.80%
Debt to equity-0.08

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)$0.00
Dividend per share
Revenue per share$6.53
Avg trading volume (30 day)$37K
Avg trading volume (10 day)$34K
Put-call ratio

Macro factor sensitivity

Growth-1.3
Credit+7.6
Liquidity+2.2
Inflation-3.1
Commodities+0.1
Interest Rates-0.7

Valuation

Dividend yield0.00%
PEG Ratio67.67
Price to sales0.58
P/E Ratio67.67
Enterprise Value to Revenue3110.95
Price to book-1.67

Upcoming events

Next earnings dayMarch 17, 2022
Next dividend day
Ex. dividend day

News

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

On Monday, RedHill Biopharma Ltd. RDHL released results from multiple  in vivo studies, undertaken by RedHill's partner, Apogee Biotechnology Corporation.

Benzinga (August 19, 2024)
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate

RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.

Zacks Investment Research (October 20, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free